Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Neurobiol Aging. 2012 Dec 20;34(5):1416–1425. doi: 10.1016/j.neurobiolaging.2012.11.014

Fig. 2.

Fig. 2

Dot-blot and Western-blot analyses of ABri/ADan N-terminal antibodies. AB76-2 showed a clear preference for pGlu-modified peptides, whereas AB77 detected ABri and pGlu-ABri peptides in a similar fashion (A). Western-blot analysis corroborated this finding showing only a minor cross-reactivity with non-modified ABri peptides at higher amounts of peptide (250 ng) and a clear preference for pGlu-modified ABri and ADan peptides using AB76-2 (B).